{"nctId":"NCT01529203","briefTitle":"Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range","startDateStruct":{"date":"2012-02"},"conditions":["Aging"],"count":60,"armGroups":[{"label":"Azzalure and Restylane","type":"OTHER","interventionNames":["Drug: Botulinum Toxin Type A (Azzalure)","Device: Restylane ranges"]}],"interventions":[{"name":"Botulinum Toxin Type A (Azzalure)","otherNames":[]},{"name":"Restylane ranges","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Male or female subjects, aged 18 to 64 years, seeking treatment for correction of dynamic wrinkles of the upper third of the face and correction of facial volume loss, and meeting other specific eligibility criteria\n\nMain Exclusion Criteria:\n\n* Female subject who is pregnant, nursing or planning a pregnancy during the study\n* Subject with any contraindications to the injection of hyaluronic acid (see package inserts)\n* Subject with any contraindications to the injection of botulinum toxin (see package insert)\n* Subject with a personal history of allergic/anaphylactic reactions including hypersensitivity to crossed-linked hyaluronic acid or botulinum toxin\n* Concurrent treatment that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of at least one of the study treatments\n* Subject with a history of dissatisfaction with facial aesthetic procedures involving dermal implant injections or subject with unattainable expectations\n* Subject currently enrolled in another investigational study or who participated in such a study in the past 30 days prior to baseline visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subject Satisfaction for the Full Face","description":"based on the subject's satisfaction questionnaire","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Aesthetic Improvement From Baseline","description":"The scale responses are: -1 indicating \"worse\", 0 indicating \"no change\", 1 indicating \"improved\", 2 indicating \"much improved\" and 3 indicating \"very much improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Related Adverse Event","description":"Number of subjects reporting related adverse events","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":60},"commonTop":["Skin swelling","Nasopharyngitis","Injection site haematoma","contusion","headache"]}}}